Search Browse Earnings

Fusion Pharmaceuticals Inc.

Biological Products, (No Diagnostic Substances)·HAMILTON, A6

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$1.5M

+1.5% YoY

FY 2023

Adj. EBITDA

-$87.1M

-5963.4% margin

FY 2023

Net Income

-$87.6M

-5996.7% margin

FY 2023

EPS (Diluted)

-$2.00

FY 2023

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$43.9M

FY 2023

Total Debt

$34.2M

FY 2023

Net Cash

$9.6M

FY 2023

Enterprise Value

—

Debt / EBITDA

0.1x

FY 2023

EV / EBITDA

—

Employees

—